Spyre Therapeutics, Inc.

Contributing Author

Recent Articles by Spyre Therapeutics, Inc.

Jun-05	Spyre Therapeutics Announces Grants of Inducement Awards SYRE -6.15% GlobeNewswire
Jun-03	Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA SYRE +6.30% GlobeNewswire
May-26	Spyre Therapeutics to Participate in Upcoming June Investor Conferences SYRE GlobeNewswire
May-05	Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update SYRE GlobeNewswire
May-01	Spyre Therapeutics Announces Grants of Inducement Awards SYRE -6.76% GlobeNewswire
Apr-16	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million SYRE GlobeNewswire
Apr-14	Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock SYRE +7.78% GlobeNewswire
Apr-13	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock SYRE +23.36% GlobeNewswire
Apr-13	Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients SYRE +23.36% GlobeNewswire
Apr-10	Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 SYRE GlobeNewswire
Apr-03	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Mar-16	Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026 SYRE +10.48% GlobeNewswire
Mar-06	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Feb-24	Spyre Therapeutics to Participate in Upcoming March Investor Conferences SYRE GlobeNewswire
Feb-19	Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update SYRE +14.28% SYRE GlobeNewswire
Feb-18	Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach SYRE GlobeNewswire
Feb-06	Spyre Therapeutics Announces Grants of Inducement Awards SYRE +6.62% GlobeNewswire
Jan-23	Spyre Therapeutics Announces Grants of Inducement Awards SYRE -6.03% GlobeNewswire
Jan-12	Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 SYRE +7.15% GlobeNewswire
Jan-08	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Dec-05	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Nov-07	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Nov-04	Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update SYRE GlobeNewswire
Nov-04	Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody SYRE GlobeNewswire
Oct-29	Spyre Therapeutics to Participate in Upcoming November Investor Conferences SYRE GlobeNewswire
Oct-24	Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 SYRE GlobeNewswire
Oct-15	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million SYRE +5.67% GlobeNewswire
Oct-13	Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock SYRE +11.02% GlobeNewswire
Oct-13	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants SYRE +11.02% SYRE GlobeNewswire
Oct-05	Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 SYRE GlobeNewswire
Oct-03	Spyre Therapeutics Announces Grants of Inducement Awards SYRE GlobeNewswire
Sep-15	Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases SYRE -5.18% GlobeNewswire

Spyre Therapeutics, Inc.

Recent Articles by Spyre Therapeutics, Inc.

Upgrade your Finviz experience